Treatment of β-thalassemia patients with recombinant human erythropoietin: Effect on transfusion requirements and soluble adhesion molecules

Acta Haematologica

Volumn 111, Issue 4, 2004, Pages 189-195

  Chaidos, Aristeidis ^a   Makis, Alexandros ^a   Hatzimichael, Eleftheria ^a   Tsiara, Stavroula ^a   Gouva, Maria ^a   Tzouvara, Evangelia ^a   Bourantas, Konstantinos L ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE   (Greece)

Author keywords

Thalassemia; Adhesion molecules; Endothelin; Erythropoietin; Recombinant human erythropoietin; Transfusion

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIN 3; HEMOGLOBIN F; RECOMBINANT ERYTHROPOIETIN; SELECTIN; TRANSFERRIN RECEPTOR;

ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; THROMBOSIS; TRANSFERRIN BLOOD LEVEL; TRANSFUSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CELL ADHESION MOLECULES; E-SELECTIN; ENDOTHELIN-3; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FETAL HEMOGLOBIN; HEMOGLOBINS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; RECEPTORS, TRANSFERRIN; SOLUBILITY; TREATMENT OUTCOME;

EID: 2642529230     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077551     Document Type: Article

References (28)

1. Loukopoulos D: Current status of thalassemia and the sickle cell syndromes in Greece. Semin Hematol 1996;33:76-86.
2. Weatherall DJ, Clegg JB: Genetic disorders of hemoglobin. Semin Hematol 1999;36(4 suppl 7):24-37.
3. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Agostinelli F, Albertini F, Clift RA: Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993;329:840-844.
4. Li Q, Emery DW, Fernandez M, Han H, Stamatoyannopoulos G: Development of viral vectors for gene therapy of beta-chain hemoglobinopathies: Optimization of a gamma-globin gene expression cassette. Blood 1999;93:2208-2216.
5. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG: Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984;310:869-873.
6. Veith R, Papayannopoulou T, Kurachi S, Stamatoyannopoulos G: Treatment of baboon with vinblastine: Insights into the mechanisms of pharmacologic stimulation of Hb F in the adult. Blood 1985;66:456-459.
7. Al Khatti A, Veith RW, Papayannopoulou T, Fritsch EF, Goldwasser E, Stamatoyannopoulos G: Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987;317:415-420.
8. Leroy-Viard K, Rouyer-Fessard P, Beuzard Y: Improvement of mouse beta-thalassemia by recombinant human erythropoietin. Blood 1991;78:1596-1602.
9. Said AA, Yamaguchi T, Uchida E, Hayakawa T: Characterization of haemolyser-resistant cells increased in the blood of erythropoietin-treated mice. Br J Haematol 1994;86:361-365.
10. Galanello R, Stamatoyannopoulos G, Papayannopoulou T: Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea. J Clin Invest 1988;81:1209-1216.
11. Rachmilewitz EA, Goldfarb A, Dover G: Administration of erythropoietin to patients with beta-thalassemia intermedia: A preliminary trial. Blood 1991;78:1145-1147.
12. Olivieri NF, Freedman MH, Perrine SP, Dover GJ, Sheridan B, Essentine DL, Nagel RL: Trial of recombinant human erythropoietin: Three patients with thalassemia intermedia. Blood 1992;80:3258-3260.
13. Bourantas K, Economou G, Georgiou J: Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: A preliminary trial. Eur J Haematol 1997;58:22-25.
14. Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL: Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. Ann Hematol 2001;80:492-495.
15. Olivieri NF, Mackinson J, Collons AF, Sher G: Long-term treatment with recombinant human erythropoietin in patients with thalassemia: Reduction in requirements for transfusion and chelation therapy. Sickle cell disease and thalassemia; in Beuzard Y, Lubin B, Resa J (eds): New Trends in Therapy. Paris, INSERM/Libbey Eurotext, 1995, pp 203-205.
16. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G: Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol 1999;106:178-181.
17. Butthep P, Bunyaratvej A, Kitaguchi H, Funahara Y, Fucharoen S: Interaction between endothelial cells and thalassemic red cells in vitro. Southeast Asian J Trop Med Public Health 1992;23(suppl 2):101-104.
18. Levin ER: Endothelins. N Engl J Med 1995;333:356-363.
19. Goodnough LT, Monk TG, Andriole GL: Erythropoietin therapy. N Engl J Med 1997;336:933-938.
20. Bourantas KL, Xenakis TA, Hatzimichael EC, Kontogeorgakos V, Beris AE: Peri-operative use of recombinant human erythropoietin in Jehovah's Witnesses. Haematologica 2000;85:444-445.
21. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N, Basak N: Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia. Acta Haematol 1997;98:199-203.
22. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG: Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000;59:419-425.
23. Dore F, Bonfigli S, Gaviano E, Pardini S, Cianciulli P, Papa G, Longinotti M: Serum erythropoietin levels in thalassemia intermedia. Ann Hematol 1993;67:183-186.
24. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA: Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102-107.
25. Beguin Y, Clemons GK, Pootrakul P, Fillet G: Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067-1076.
26. Binley K, Askham Z, Iqball S, Spearman H, Martin L, de Alwis M, Thrasher AJ, Ali RR, Maxwell PH, Kingsman S, Naylor S: Longterm reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002;100:2406-2413.
27. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
28. Voulgari PV, Chaidos A, Tzouvara E, Alymara V, Alamanos Y, Drosos AA, Bourantas KL: Antierythropoietin antibodies in thalassemia patients. Ann Hematol 2004;83:22-27.